Cantor Fitzgerald Reaffirms “Overweight” Rating for Mereo BioPharma Group (NASDAQ:MREO)
Mereo BioPharma Group (NASDAQ:MREO – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 171.32% from the stock’s current price. Several other […]
Mereo BioPharma Group (NASDAQ:MREO – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 171.32% from the stock’s current price. Several other […]
